25
Participants
Start Date
May 13, 2013
Primary Completion Date
December 22, 2015
Study Completion Date
December 22, 2015
GSK2398852
Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
GSK2315698
Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
GSK Investigational Site, Cambridge
GSK Investigational Site, London
Lead Sponsor
Imperial College London
OTHER
Heart Hospital
UNKNOWN
Royal Free Hospital NHS Foundation Trust
OTHER
Quintiles, Inc.
INDUSTRY
GlaxoSmithKline
INDUSTRY